These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1212 related articles for article (PubMed ID: 25482930)

  • 1. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
    Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
    Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects.
    Yu R; Deedigan L; Albarenque SM; Mohr A; Zwacka RM
    Cell Death Dis; 2013 Feb; 4(2):e503. PubMed ID: 23429289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRAIL-receptor preferences in pancreatic cancer cells revisited: Both TRAIL-R1 and TRAIL-R2 have a licence to kill.
    Mohr A; Yu R; Zwacka RM
    BMC Cancer; 2015 Jul; 15():494. PubMed ID: 26138346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of soluble tumor necrosis factor-related apoptosis-inducing ligand released by engineered adipose mesenchymal stromal cells on white blood cells.
    Casari G; Dall'Ora M; Melandri A; Masciale V; Chiavelli C; Prapa M; Neri G; Spano MC; Murgia A; D'Esposito A; Baschieri MC; Ceccherelli GB; Dominici M; Grisendi G
    Cytotherapy; 2023 Jun; 25(6):605-614. PubMed ID: 37012089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel TRAIL mutant-TRAIL-Mu3 enhances the antitumor effects by the increased affinity and the up-expression of DR5 in pancreatic cancer.
    Huang M; Zhu H; Yi C; Yan J; Wei L; Yang X; Chen S; Huang Y
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):829-838. PubMed ID: 30167846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design.
    Tur V; van der Sloot AM; Reis CR; Szegezdi E; Cool RH; Samali A; Serrano L; Quax WJ
    J Biol Chem; 2008 Jul; 283(29):20560-8. PubMed ID: 18474604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulation of intracellular anti-apoptotic proteins, particularly c-FLIP by therapeutic agents; the novel view to overcome resistance to TRAIL.
    Hassanzadeh A; Farshdousti Hagh M; Alivand MR; Akbari AAM; Shams Asenjan K; Saraei R; Solali S
    J Cell Physiol; 2018 Oct; 233(10):6470-6485. PubMed ID: 29741767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chalepin: A Compound from
    Richardson JSM; Aminudin N; Abd Malek SN
    Pharmacogn Mag; 2017 Oct; 13(Suppl 3):S489-S498. PubMed ID: 29142404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL ligand inhibits metastatic growth of pancreatic carcinoma cells.
    Mohr A; Albarenque SM; Deedigan L; Yu R; Reidy M; Fulda S; Zwacka RM
    Stem Cells; 2010 Nov; 28(11):2109-20. PubMed ID: 20882532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRAIL induces apoptosis but not necroptosis in colorectal and pancreatic cancer cells preferentially via the TRAIL-R2/DR5 receptor.
    Nahacka Z; Svadlenka J; Peterka M; Ksandrova M; Benesova S; Neuzil J; Andera L
    Biochim Biophys Acta Mol Cell Res; 2018 Mar; 1865(3):522-531. PubMed ID: 29278689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
    Hari Y; Harashima N; Tajima Y; Harada M
    Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
    Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
    Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells.
    Khanbolooki S; Nawrocki ST; Arumugam T; Andtbacka R; Pino MS; Kurzrock R; Logsdon CD; Abbruzzese JL; McConkey DJ
    Mol Cancer Ther; 2006 Sep; 5(9):2251-60. PubMed ID: 16985059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations Enhancing Selectivity of Antitumor Cytokine TRAIL to DR5 Receptor Increase Its Cytotoxicity against Tumor Cells.
    Gasparian ME; Bychkov ML; Yagolovich AV; Dolgikh DA; Kirpichnikov MP
    Biochemistry (Mosc); 2015 Aug; 80(8):1080-91. PubMed ID: 26547077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells.
    Bremer E; de Bruyn M; Samplonius DF; Bijma T; ten Cate B; de Leij LF; Helfrich W
    J Mol Med (Berl); 2008 Aug; 86(8):909-24. PubMed ID: 18504532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IRF-1 inhibits NF-κB activity, suppresses TRAF2 and cIAP1 and induces breast cancer cell specific growth inhibition.
    Armstrong MJ; Stang MT; Liu Y; Yan J; Pizzoferrato E; Yim JH
    Cancer Biol Ther; 2015; 16(7):1029-41. PubMed ID: 26011589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL.
    Gómez-Benito M; Martinez-Lorenzo MJ; Anel A; Marzo I; Naval J
    Exp Cell Res; 2007 Jul; 313(11):2378-88. PubMed ID: 17462628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death.
    Ibrahim SM; Ringel J; Schmidt C; Ringel B; Müller P; Koczan D; Thiesen HJ; Löhr M
    Pancreas; 2001 Jul; 23(1):72-9. PubMed ID: 11451151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4.
    Kurbanov BM; Fecker LF; Geilen CC; Sterry W; Eberle J
    Oncogene; 2007 May; 26(23):3364-77. PubMed ID: 17160022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-hairpin RNA-induced suppression of adenine nucleotide translocase-2 in breast cancer cells restores their susceptibility to TRAIL-induced apoptosis by activating JNK and modulating TRAIL receptor expression.
    Jang JY; Jeon YK; Choi Y; Kim CW
    Mol Cancer; 2010 Sep; 9():262. PubMed ID: 20875141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.